肺癌驱动基因研究总结.pptxVIP

非小细胞肺癌驱动基因研究;Treatment selection is moving from histology-based to targeting oncogenic drivers;NSCLC肿瘤驱动基因;Frequency of driver genes in subgroups of NSCLC in Chinese;Frequency of driver genes in subgroups of NSCLC in Chinese;91%抗肿瘤药物的敏感性与基因变异相关;Significantly Mutated Genes in Squamous Cell Lung Cancer;;第一个有临床意义的NSCLC驱动基因：; ;Placebo;PFS according to IRC;;;;;Nature Medicine 18(8):521, 2012;EURTAC Biomarker Study;疗效持续时间：基线到首次PD时间； 肿瘤负荷：靶病灶倍增时间 和非靶病灶评分（4分）：病变进展、新出现胸内病变、新出现胸外 病 变、恶性胸腔积液 症状评分：无症状（0）、原有症状稳定（1）、症状恶化（2）;NSCLC驱动基因;PROFILE 1007: Crizotinib vs Chemotherapy (2nd/3rd line therapy);aRECIST v1.1;Primary Endpoint: PFS by Independent Radiologic Review (ITT Population);;PFS Subgroup Analysis; ;Phase III PROFILE 1014 (n=334) ALK-positive locally advanced/ metastatic non-squamous NSCLC No prior treatment for advanced disease;Ph-I: LDK378 is active in ALK+ NSCLC High response rate in crizotinib relapsed patients;NSCLC驱动基因;ROS1临床病例;;NSCLC驱动基因;CR, complete response; PR, partial response; SD, stable diseasePD, progressive disease; DoR, duration of response; APF6, alive and progression-free at 6 months;;NSCLC驱动基因;33岁，非吸烟，EGFRKRASALK均(-) 新发现存在KIF5B-RET融合基因表达 RETinhibitor有效;DDR2突变鳞癌患者Dasatinib治疗有效;Mutation identified;2012 NSCLC肿瘤驱动基因的加速发现;A Novel Classification of Lung Cancer into Molecular Subtypes;;谢谢;Frequency of driver genes in subgroups of NSCLC in Chinese;Frequency of driver genes in subgroups of NSCLC in Chinese;Significantly Mutated Genes in Squamous Cell Lung Cancer;Placebo;;NSCLC驱动基因;Phase III PROFILE 1014 (n=334) ALK-positive locally advanced/ metastatic non-squamous NSCLC No prior treatment for advanced disease;谢谢